Synlogic. has filed a patent for a recombinant bacterium that can produce D-lactate and/or L-lactate. The bacterium contains an ldhA gene that is linked to an inducible promoter, which can be activated by external environmental conditions. The invention also includes pharmaceutical compositions and methods for treating diseases. GlobalData’s report on Synlogic gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Synlogic Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Synlogic, Peptide pharmacophores was a key innovation area identified from patents. Synlogic's grant share as of September 2023 was 17%. Grant share is based on the ratio of number of grants to total number of patents.

Recombinant bacteria for producing d-lactate

Source: United States Patent and Trademark Office (USPTO). Credit: Synlogic Inc

A recently filed patent (Publication Number: US20230293603A1) describes a recombinant bacterium that produces D-lactate. The bacterium contains an ldhA gene that is linked to an inducible promoter, which can be activated by specific environmental conditions. Additionally, the bacterium may have deletions or mutations in genes such as pta, pflB, and ackA. These genetic modifications enhance the production of D-lactate. The bacterium can be present on a plasmid or chromosome and can belong to non-pathogenic or probiotic/commensal species such as Bacteroides, Bifidobacterium, Clostridium, Escherichia, Lactobacillus, and Lactococcus. It is capable of producing D-lactate in vitro at concentrations ranging from 1 mM to 20 mM.

The patent also covers a pharmaceutically acceptable composition comprising the bacterium and a carrier, formulated for oral administration. This composition can be used to treat various diseases and disorders, particularly autoimmune and inflammatory conditions such as multiple sclerosis, colitis, rheumatoid arthritis, celiac disease, myasthenia gravis, and B-cell-mediated T-cell-dependent autoimmune disease. The composition can reduce or ameliorate symptoms of inflammation in these diseases. The method of treatment involves administering the pharmaceutical composition to a subject, preferably a human, and monitoring the levels of D-lactate or L-lactate in urine before and after administration. An increase in lactate levels indicates the efficacy of the treatment. The composition can also repress effector T cells, increase expression of Hypoxia-inducible factor 1-alpha (HIF-1a) in dendritic cells, and decrease re-stimulation of T cells, providing additional therapeutic benefits.

Overall, this patent describes a genetically modified bacterium capable of producing D-lactate, which can be used in a pharmaceutical composition for the treatment of autoimmune and inflammatory diseases. The composition shows potential in reducing inflammation and modulating immune responses.

To know more about GlobalData’s detailed insights on Synlogic, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies